Top Menu

studi praklinis baru menunjukkan vaksin untuk mencegah infeksi Zika pada manusia adalah layak -T-REC semarang--komunitas reptil-semarang--KSE-komunitas satwa eksotik—komunitas semarang—komunitas reptil—komunitas reptil semarang—komunitas satwa—komunitas satwa semarang--berita artikel terkait tentang zika,praklinis

studi praklinis baru menunjukkan vaksin untuk mencegah infeksi Zika pada manusia adalah layak
ilmuwan militer bergerak cepat untuk menguji calon vaksin
Date:
June 28, 2016
Source:
The U.S. Military HIV Research Program (MHRP)
Summary:
Walter Reed Army Institute of Research (WRAIR) dan kolaborator di Deaconess Medical 
Center Beth Israel dan Harvard Medical School telah menyelesaikan studi praklinis 
menjanjikan dua kandidat vaksin Zika yang menunjukkan bahwa vaksin manusia yang 
efektif akan dicapai. Temuan dari penelitian ini diterbitkan dalam jurnal Nature.

..........................
Walter Reed Army Institute of Research (WRAIR) dan kolaborator di Deaconess Medical 
Center Beth Israel dan Harvard Medical School telah menyelesaikan studi praklinis 
menjanjikan dua kandidat vaksin Zika yang menunjukkan bahwa vaksin manusia yang 
efektif akan dicapai. Temuan dari penelitian ini diterbitkan dalam jurnal Nature.
 
Dalam studi praklinis, WRAIR dan Medical Center Beth Israel Deaconess menguji  
dua kandidat vaksin virus Zika: vaksin DNA dikembangkan di Harvard
 berdasarkan strain virus Zika yang diisolasi di Brazil, dan vaksin virus yang
 tidak aktif dimurnikan yang dikembangkan di WRAIR berdasarkan pada 
strain virus Zika terisolasi di Puerto Rico.


............................
SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

.................
........................................
........................................
........................................
........................................





T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA


More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
MORE  INFO : KUNJUNGI  www.trecsemarang2011.blogspot.com
MORE  INFO : KUNJUNGI  www.trecsemarang2011.blogspot.com
MORE  INFO : KUNJUNGI  www.trecsemarang2011.blogspot.com
MORE  INFO : KUNJUNGI  www.trecsemarang2011.blogspot.com
MORE  INFO : KUNJUNGI  www.trecsemarang2011.blogspot.com
MORE  INFO : KUNJUNGI  www.trecsemarang2011.blogspot.com

FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2




..................................
..................................
..................................
KSE – KOMUNITAS SATWA EKSOTIK –
EXOTIC PETS COMMUNITY-- INDONESIA


Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/



 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK :
www.komunitassatwaeksotik-pendaftaran.blogspot.com

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI   :  08995557626


FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
FAST  RESPON : 08995557626/764047D2
 ........Komunitas T-REC semarang,komunitas reptil tugumuda reptiles community semarang,komunitas reptil tugumuda semarang,komunitas semarang,komunitas reptil semarang.............kenali dan dalami satwa dan reptil  dengan bergabung bersama kami,hubungi 08995557626 / 764047D2.....

........Komunitas KSE ,komunitas satwa eksotik ,komunitas satwa.............kenali dan dalami satwa dan reptil  dengan bergabung bersama kami,hubungi 08995557626 / 764047D2.....

.............................


................

New preclinical study indicates vaccine to prevent Zika infection in humans is feasible

Army scientists are moving quickly to test vaccine candidate

Date:
June 28, 2016
Source:
The U.S. Military HIV Research Program (MHRP)
Summary:
The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable. Findings from the study were published today in the journal Nature.
..........................
The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable. Findings from the study were published today in the journal Nature.
In the preclinical study, WRAIR and the Beth Israel Deaconess Medical Center tested two Zika virus vaccine candidates: a DNA vaccine developed at Harvard based on a Zika virus strain isolated in Brazil, and a purified inactivated virus vaccine developed at WRAIR based on a Zika virus strain isolated in Puerto Rico.
The study showed that single shots of either vaccine candidate protected mice against subsequent Zika challenge. Both candidates were found to be safe and elicited an antibody response to Zika virus that correlated with protection. Further work with the DNA vaccine demonstrated that protection was solely due to antibodies raised by vaccination.
WRAIR is moving forward with the purified inactivated virus (PIV) vaccine, called ZPIV, because it builds on "a type of vaccine that has been licensed before," said Col. Stephen Thomas, an infectious disease Army physician and a vaccinologist specializing in flaviviruses, and the WRAIR Zika program lead. "It's the same technology WRAIR has used to successfully develop other flavivirus vaccines." Researchers are trying to mitigate risk by avoiding unproven technologies that could cause a licensing delay, he noted.
Col. Nelson Michael, the WRAIR Zika program co-lead, said, "This critical first step has informed our ongoing work in non-human primates and gives us early confidence that development of a protective Zika virus vaccine for humans is feasible."
WRAIR scientists are moving rapidly to develop and test the ZPIV vaccine, and they plan to start human testing at their clinic in Silver Spring before the end of the year. Additional human trials are planned in the United States, supported by the National Institute of Allergy and Infectious Diseases (NIAID), through its Vaccine and Treatment Evaluation Units.
WRAIR has been researching flaviviruses, a family of viruses that includes Japanese encephalitis, dengue, West Nile and Zika viruses, for over half a century. "Our laboratory in Thailand has been conducting biosurveillance for Zika for the past three years, since we started to observe dengue-like illnesses in Thailand and the Philippines that were not dengue and did not test positive for other likely causes," said Thomas. "These efforts gave us a head-start for our vaccine development efforts."
WRAIR also has in-house capabilities that have enabled them to quickly develop a vaccine candidate. The Pilot Bioproduction Facility headed by Dr. Kenneth H. Eckels, produced small batches of vaccine candidates that were used for the preclinical studies and is currently manufacturing a vaccine lot for use in initial human clinical studies.
Infectious diseases have long been a threat to U.S. Service Members, and the military has extensive expertise and capabilities to develop countermeasures. WRAIR is working on the vaccine in collaboration with other U.S. government agencies, including the NIAID, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services. It is also exploring collaborations with pharmaceutical companies.
Support for this study was provided by the National Institutes of Health (AI095985, AI096040, AI00663 and AI124377), the Ragon Institute of MGH, MIT and Harvard, and the Sao Paulo Research Foundation.


Story Source:
The above post is reprinted from materials provided by The U.S. Military HIV Research Program (MHRP)Note: Materials may be edited for content and length.


Journal Reference:
1.    Rafael A. Larocca, Peter Abbink, Jean Pierre S. Peron, Paolo M. de A. Zanotto, M. Justin Iampietro, Alexander Badamchi-Zadeh, Michael Boyd, David Ng’ang’a, Marinela Kirilova, Ramya Nityanandam, Noe B. Mercado, Zhenfeng Li, Edward T. Moseley, Christine A. Bricault, Erica N. Borducchi, Patricia B. Giglio, David Jetton, George Neubauer, Joseph P. Nkolola, Lori F. Maxfield, Rafael A. De La Barrera, Richard G. Jarman, Kenneth H. Eckels, Nelson L. Michael, Stephen J. Thomas, Dan H. Barouch. Vaccine protection against Zika virus from BrazilNature, 2016; DOI: 10.1038/nature18952


Share this:

 
Designed By OddThemes | Distributed By Gooyaabi Templates